← Back to patent-cliff list
TDM-Atop-01
Tier C — Watch / tradeTDM-Atop-01
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Dermatitis, Eczema
Regional status
US
-
EU
-
China
Phase II
2025-09-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TDM-Atop-01?
Approved indications include: Dermatitis, Eczema.
When does the TDM-Atop-01 patent expire?
No public expiry year is available for TDM-Atop-01 yet; this page updates once verified.
How do I get a quote for TDM-Atop-01 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30